GoodRx Holdings, Inc. operates a digital healthcare platform focused on prescription and medication savings in the United States. Company news commonly covers prescription transaction revenue, retail pharmacy trends, negotiated discount pricing, PBM relationships, and the expansion of Pharma Direct manufacturer programs that connect branded drug discounts to consumers at the pharmacy counter.
GoodRx updates also include self-pay pricing arrangements for GLP-1 and other branded medications, subscription health services such as condition-specific programs, earnings releases, business outlook commentary, and partnerships with pharmaceutical manufacturers, pharmacies, payers, and healthcare professionals.
GoodRx (GDRX) launched the GoodRx Companion Family Plan, a subscription that extends healthcare savings to an entire household, including pets. The plan costs $24.99 per month, or $16.99 per month when paid annually, and covers a primary member plus up to four dependents.
Members can access more than 250 eligible generic medications for free and hundreds more for under $10 at nearly every pharmacy nationwide. The plan also includes savings on dental, vision, lab and imaging services, and $19 online care visits for the primary member. GoodRx expects to make Companion available to employers through its Employer Direct offering.
GoodRx (Nasdaq: GDRX) reported second quarter 2026 revenue of $200.4 million, down 1% year-over-year. Prescription transactions revenue fell 26% to $106.4 million, while subscription revenue rose 39% to $28.5 million and Pharma Direct revenue increased 76% to $61.6 million, reflecting growth in condition-specific programs and GLP-1 access offerings.
Net income was $8.5 million (4.3% margin) versus $12.8 million, and Adjusted EBITDA was $63.7 million (31.8% margin) versus $69.4 million. Operating cash flow improved to $80.8 million from $49.6 million. As of June 30, 2026, cash and cash equivalents were $296.1 million with total debt of $492.5 million. Management raised full-year 2026 guidance to revenue of $790–$805 million (vs. $796.9 million in 2025) and Adjusted EBITDA of $240–$250 million.
GoodRx (Nasdaq:GDRX) plans to release its second quarter 2026 earnings after U.S. markets close on Wednesday, August 5, 2026. Management will host a conference call and live webcast on Thursday, August 6, 2026 at 5:00 a.m. PT (8:00 a.m. ET).
Investors must pre-register to receive dial-in details and a unique passcode. A replay will be available on the GoodRx investor relations website for at least 30 days.
GoodRx (Nasdaq:GDRX) launched GoodRx Companion, a $14.99-per-month subscription aimed at lowering everyday healthcare costs. The membership bundles free and low-cost generic drugs, $19 telehealth visits, and savings on dental, vision, lab, and imaging services.
Companion supports GoodRx’s broader, recurring-revenue subscription strategy.
GoodRx (Nasdaq: GDRX) reported Q1 2026 results: revenue $194.0M, net income $1.2M, adjusted EBITDA $58.3M (30.0% margin), and adjusted net income $23.0M (11.9% margin).
Pharma Direct revenue grew 82% to $52.2M; subscription revenue rose 16% to $24.4M. Management raised FY2026 revenue guidance to $765–$785M and expects adjusted EBITDA > $235M.
GoodRx (NASDAQ: GDRX) is adding Novo Nordisk’s Ozempic pill (oral semaglutide) to its platform with nationwide self-pay pricing. Eligible patients can access the 1.5mg dose for $149/month, 4mg for $199/month, and 9mg for $299/month. The move expands GoodRx’s semaglutide offerings and aims to provide an oral alternative to injectable treatment at retail pharmacies.
GoodRx (Nasdaq: GDRX) will release first quarter 2026 results after U.S. markets close on Wednesday, May 6, 2026.
Management will host a conference call and webcast on Thursday, May 7, 2026 at 5:00 a.m. PT (8:00 a.m. ET); materials and an archived webcast will be available on the investor relations website.
GoodRx (Nasdaq: GDRX) announced Wegovy® HD (semaglutide 7.2 mg) is available to eligible self-pay patients at a $399 per month price, with two- and three-month supplies at $798 and $1,197 respectively. GoodRx for Weight Loss offers eligibility assessment, provider visits, and prescription support nationwide.
The offering aims to expand access to FDA-approved GLP-1 dosing with upfront pricing and pharmacy fulfillment through GoodRx’s platform.
GoodRx (Nasdaq: GDRX) expanded access to Eli Lilly’s new oral GLP-1 Foundayo (orforglipron) and to Zepbound KwikPen. Eligible self-pay patients can access Foundayo starting at $149/month and Zepbound KwikPen starting at $299/month at more than 70,000 pharmacies nationwide. GoodRx said these offerings provide transparent cash pricing and nationwide pharmacy access, supporting direct-to-consumer launch models as insurance coverage for GLP-1 treatments remains inconsistent.
GoodRx reported a platform reach of nearly 25 million consumers and highlighted its role connecting manufacturers, pharmacies, clinicians, and patients.
GoodRx (Nasdaq: GDRX) and Viatris announced a collaboration to make 17 established brand medications more affordable in the U.S. Eligible commercially insured patients may pay $0–$4 on select Viatris drugs; cash prices can be discounted up to 85% off at > 70,000 pharmacies. Brands included: Lipitor, Celebrex, Viagra, and Norvasc. GoodRx cites nearly 25 million annual users and says the platform has helped save over $100 billion since 2011. The program aims to expand access and support adherence for established brands, including those navigating loss of exclusivity.